BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, Zhang J, Wong C, Wong C, Trinh H. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study. J Infect Dis 2019;219:10-8. [PMID: 29982737 DOI: 10.1093/infdis/jiy391] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Zhang FK. Recent advances in assessment and treatment of chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2019; 27(4): 209-219 [DOI: 10.11569/wcjd.v27.i4.209] [Reference Citation Analysis]
2 Mak LY, Wong DK, Cheung KS, Seto WK, Fung J, Yuen MF. First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. BMC Gastroenterol 2021;21:123. [PMID: 33731023 DOI: 10.1186/s12876-021-01711-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chang TS, Yang YH, Chen WM, Shen CH, Tung SY, Yen CW, Hsieh YY, Lee CP, Tsai ML, Hung CH, Lu SN. Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep. 2021;11:1365. [PMID: 33446835 DOI: 10.1038/s41598-020-80523-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zheng S, Liu L, Lu J, Zhang X, Shen H, Zhang H, Xue Y, Lin L. Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study. Medicine (Baltimore) 2019;98:e17590. [PMID: 31626130 DOI: 10.1097/MD.0000000000017590] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
5 Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd; North American AIDS Cohort Collaboration on Research, Design of IeDEA. Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. Hepatology 2021. [PMID: 33780007 DOI: 10.1002/hep.31839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Kaneko S, Kurosaki M, Joko K, Marusawa H, Kondo M, Kojima Y, Uchida Y, Kimura H, Tsuji K, Yagisawa H, Kusakabe A, Kobashi H, Akahane T, Tamaki N, Kirino S, Abe T, Yoshida H, Matsushita T, Hasebe C, Izumi N. Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. Sci Rep. 2020;10:13021. [PMID: 32747646 DOI: 10.1038/s41598-020-69522-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, Nam SW, Bae SH, Choi JY, Yoon SK, Han NI, Jang JW. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut 2020;69:1301-8. [PMID: 31672838 DOI: 10.1136/gutjnl-2019-318947] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
8 Tan Q. Harnessing the power of twins in epigenetic association studies: causal inference and more. Epigenomics 2020;12:1-3. [PMID: 31833395 DOI: 10.2217/epi-2019-0359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 Tran S, Jeong D, Henry L, Cheung RC, Nguyen MH. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. Am J Gastroenterol 2021;116:1885-95. [PMID: 33927125 DOI: 10.14309/ajg.0000000000001271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sharafi H, Alavian SM. The Rising Threat of Hepatocellular Carcinoma in the Middle East and North Africa Region: Results From Global Burden of Disease Study 2017. Clin Liver Dis (Hoboken) 2019;14:219-23. [PMID: 32015873 DOI: 10.1002/cld.890] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Easom NJW, Marks M, Jobe D, Gillmore R, Meyer T, Maini MK, Njie R. ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome. Front Oncol 2020;10:971. [PMID: 32656081 DOI: 10.3389/fonc.2020.00971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 31.3] [Reference Citation Analysis]
13 Lin C, Lin Y, Liang K, Chen L, Chien C, Hu C, Huang T, Shyu Y, Yeh C, Chien R. Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan. Clinical Therapeutics 2022;44:403-417.e6. [DOI: 10.1016/j.clinthera.2022.01.010] [Reference Citation Analysis]
14 Liu K, Choi J, Le A, Yip TC, Wong VW, Chan SL, Chan HL, Nguyen MH, Lim YS, Wong GL. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther 2019;50:1037-48. [PMID: 31524304 DOI: 10.1111/apt.15499] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
15 Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir. Hepatol Commun 2021. [PMID: 34532993 DOI: 10.1002/hep4.1819] [Reference Citation Analysis]
16 Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, Wang CC, Lim YS, Lai HC, Trinh HN, Wong C, Wong C, Zhang J, Li J, Kao JH. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int 2021;15:105-13. [PMID: 33547557 DOI: 10.1007/s12072-020-10124-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kim WR, Telep LE, Jump B, Lu M, Ramroth H, Flaherty J, Gaggar A, Chokkalingam AP, C Gordon S. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Aliment Pharmacol Ther 2022. [PMID: 35137422 DOI: 10.1111/apt.16786] [Reference Citation Analysis]
18 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 18.5] [Reference Citation Analysis]
19 Tseng CH, Tseng CM, Wu JL, Hsu YC, El-Serag HB. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review. J Gastroenterol Hepatol. 2020;35:1684-1693. [PMID: 32343431 DOI: 10.1111/jgh.15078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
20 Tan Q. Deciphering the DNA Methylome of Polycystic Ovary Syndrome. Mol Diagn Ther 2020;24:245-50. [DOI: 10.1007/s40291-020-00463-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Hanson J, Fox M, Anderson A, Fox P, Webster K, Williams C, Nield B, Bagshaw R, Hempenstall A, Smith S, Solomon N, Boyd P. Chronic hepatitis B in remote, tropical Australia; successes and challenges. PLoS One 2020;15:e0238719. [PMID: 32881958 DOI: 10.1371/journal.pone.0238719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Wang J, Li CD, Sun L. Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma. Biomolecules 2020;10:E301. [PMID: 32075046 DOI: 10.3390/biom10020301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Nahon P, Vo Quang E, Ganne-Carrié N. Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control. J Clin Med 2021;10:353. [PMID: 33477752 DOI: 10.3390/jcm10020353] [Reference Citation Analysis]
24 Ding B, Lou W, Liu J, Li R, Chen J, Fan W. In silico analysis excavates potential biomarkers by constructing miRNA-mRNA networks between non-cirrhotic HCC and cirrhotic HCC. Cancer Cell Int. 2019;19:186. [PMID: 31346321 DOI: 10.1186/s12935-019-0901-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
25 Wang X, Liu X, Wang P, Yu L, Yan F, Yan H, Zhou D, Yang Z. Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia. J Hepatocell Carcinoma 2021;8:1253-67. [PMID: 34708007 DOI: 10.2147/JHC.S330301] [Reference Citation Analysis]
26 Toy M, Hutton D, Harris AM, Nelson N, Salomon JA, So S. Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. Clin Infect Dis 2021:ciab405. [PMID: 33956937 DOI: 10.1093/cid/ciab405] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yang S, Ma X, Cai C, Wang H, Xiao F, Yu C. Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study. Front Med (Lausanne) 2021;8:637126. [PMID: 33791326 DOI: 10.3389/fmed.2021.637126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lee SW, Choi J, Kim SU, Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:402-12. [PMID: 34157830 DOI: 10.3350/cmh.2021.0179] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Manne V, Gochanour E, Kowdley KV. Current perspectives into the evaluation and management of hepatitis B: a review. Hepatobiliary Surg Nutr 2019;8:361-9. [PMID: 31489305 DOI: 10.21037/hbsn.2019.02.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
30 Hsu Y, Wong GL, Chen C, Peng C, Yeh M, Cheung K, Toyoda H, Huang C, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai P, Huang Y, Wong C, Huang R, Jang T, Hoang J, Yang H, Li J, Lee D, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen M, Yu M, Nguyen MH. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. Am J Gastroenterol 2020;115:271-80. [DOI: 10.14309/ajg.0000000000000428] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
31 Kawanaka M, Nishino K, Kawamoto H, Haruma K. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol 2021; 27(43): 7497-7508 [PMID: 34887645 DOI: 10.3748/wjg.v27.i43.7497] [Reference Citation Analysis]
32 Suzuki T, Matsuura K, Nagura Y, Iio E, Ogawa S, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection. PLoS One 2021;16:e0261878. [PMID: 34962955 DOI: 10.1371/journal.pone.0261878] [Reference Citation Analysis]
33 Choi WM, Choi J, Lim YS. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021;19:246-258.e9. [PMID: 32407970 DOI: 10.1016/j.cgh.2020.05.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
34 Sanai FM, Alghamdi M, Dugan E, Alalwan A, Al-Hamoudi W, Abaalkhail F, AlMasri N, Razavi-Shearer D, Razavi H, Schmelzer J, Alfaleh FZ. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia. J Infect Public Health 2020;13:1715-23. [PMID: 32988769 DOI: 10.1016/j.jiph.2020.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]